|GSK2033 is a potent LXR antagonist.
|GW3965 hydrochloride is a selective, orally active non-steroidal synthetic liver X receptor (LXR) agonist.
|RGX-104 hydrochloride is a small-molecule LXR (liver X receptor) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
|Iristectorigenin B is a liver X receptor (LXR) modulator, which stimulates the transcriptional activity of both LXR-α and LXR-β.
|Yamogenin (Diosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay.
|SR9238 is a liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
|LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
|SR9243 is a potent and selective LXR inverse agonist.
|T0901317 is a potent and selective agonist for both LXRα and LXRβ with an EC50 of ~ 50 nM.
|GW6340 is an intestinal-specific LXR agonist.
|Larsucosterol is an endogenous sulfated oxysterol and a potent hepatic X receptor (LXR) and DNA methylase (DNMTS) antagonist that regulates endogenous lipogenesis as well as inhibits cholesterol biosynthesis by lowering mRNA levels and inhibiting SREBP-1 activation. May be used in studies related to psoriasis.
|24(S)-Hydroxycholesterol (24S-OHC), the major brain cholesterol metabolite, plays an important role to maintain homeostasis of cholesterol in the brain. 24(S)-Hydroxycholesterol (24S-OHC) is one of the most efficient endogenous LXR agonist known and is present in the brain and in the circulation at relatively high levels. 24(S)-Hydroxycholesterol (24S-OHC) is a very potent, direct, and selective positive allosteric modulator of NMDARs with a mechanism that does not overlapthat of other allosteric modulators.
|GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.
|GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation.
|BMS-779788 is a LXR partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.
|RGX-104, also known as SB 742881, is a liver X receptor beta (LXR) agonist with potential immunomodulating and antineoplastic activities.
|IMB-808 is a potent Liver X receptor α and β (LXRα/β) partial dual agonist that promotes expression of genes related to reverse cholesterol transport (including ABCA1 and ABCG1), and associated with cholesterol metabolism pathway in multiple cell lines (including ApoE).
|TFCA is a Liver X receptor α (LXRα) antagonist that reduces lipid accumulation and fatty liver in mice.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.